UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 5 von 10
Datensatz exportieren als...
BibTeX
Phase I Trial of an Interleukin-2 (IL-2) Fusion Toxin (DAB486IL-2) in Hematologic Malignancies Expressing the IL-2 Receptor
Blood, 1992-05, Vol.79 (10), p.2547-2554
LeMaistre, C.F.
Meneghetti, C.
Rosenblum, M.
Reuben, J.
Parker, K.
Shaw, J.
Deisseroth, A.
Woodworth, T.
Parkinson, D.R.
1992
Details
Autor(en) / Beteiligte
LeMaistre, C.F.
Meneghetti, C.
Rosenblum, M.
Reuben, J.
Parker, K.
Shaw, J.
Deisseroth, A.
Woodworth, T.
Parkinson, D.R.
Titel
Phase I Trial of an Interleukin-2 (IL-2) Fusion Toxin (DAB486IL-2) in Hematologic Malignancies Expressing the IL-2 Receptor
Ist Teil von
Blood, 1992-05, Vol.79 (10), p.2547-2554
Ort / Verlag
Washington, DC: Elsevier Inc
Erscheinungsjahr
1992
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
DAB486IL-2 is a recombinant fusion toxin in which the native receptor binding domain of diphtheria toxin has been replaced with human interleukin-2 (IL-2). It selectively binds and intoxicates only cells that bear the high-affinity receptor for IL-2. In the first clinical trial of a genetically engineered ligand fusion-toxin, we have treated 18 patients with chemo-therapy-resistant IL-2 receptor expressing hematologic malignancies with escalating doses of DAB486IL-2. The maximal tolerated dose of a daily intravenous bolus of DAB486IL-2 was 0.1 mg/kg per day for 10 doses, established by asymptomatic, reversible elevations of hepatic transaminases without changes in other tests of liver function. Other mild reversible side effects noted were rash, nausea, elevated creatinine, chest tightness, and fever. Pharmacokinetic analysis showed a monophasic clearance of 5.8 ± 0.7 minutes with peak levels of 3,549 ± 1,041 mg/mL at the 0.1 mg/kg dose. Approximately 50% of patients developed an antibody response to diphtheria toxin or DAB486IL-2. The presence of such antibodies did not preclude patients from experiencing an antitumor response as four of the six patients with antitumor effect had detectable antibody titers. Although this was a phase I trial designed to define the safety of DAB486IL-2, remissions were observed in three patients lasting from 5 to over 18 months. The ability to achieve significant tumor reductions in this group of heavily treated patients is encouraging and suggests additional trials are warranted in hematologic malignancies. © 1992 by The American Society of Hematology
Sprache
Englisch
Identifikatoren
ISSN: 0006-4971
eISSN: 1528-0020
DOI: 10.1182/blood.V79.10.2547.2547
Titel-ID: cdi_crossref_primary_10_1182_blood_V79_10_2547_2547
Format
–
Schlagworte
Adult
,
Aged
,
Antibodies, Monoclonal
,
Antibody Formation
,
Antigens, CD - analysis
,
Antineoplastic agents
,
Biological and medical sciences
,
Diphtheria Toxin - pharmacokinetics
,
Diphtheria Toxin - therapeutic use
,
Diphtheria Toxin - toxicity
,
Dose-Response Relationship, Drug
,
Drug Evaluation
,
Female
,
Hodgkin Disease - therapy
,
Humans
,
Immunotherapy
,
Immunotoxins - therapeutic use
,
Immunotoxins - toxicity
,
Interleukin-2 - pharmacokinetics
,
Interleukin-2 - therapeutic use
,
Interleukin-2 - toxicity
,
Leukemia, Lymphocytic, Chronic, B-Cell - immunology
,
Leukemia, Lymphocytic, Chronic, B-Cell - therapy
,
Lymphoma - immunology
,
Lymphoma - therapy
,
Lymphoma, Non-Hodgkin - therapy
,
Male
,
Medical sciences
,
Middle Aged
,
Pharmacology. Drug treatments
,
Receptors, Interleukin-2 - analysis
,
Recombinant Fusion Proteins - therapeutic use
,
Recombinant Fusion Proteins - toxicity
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX